-
25-06-2019, 10:36 AM
#17021
Originally Posted by Balance
Same Kaiser that PEB was waxing lyrical about as being the game changing transformative customer - until it all went quiet last year and flat like Jacinda's Kiwibuild?
Excerpt from Sep 2016 report :
"However, we are well advanced in our commercial progress with these organisations,
having signed the Federal Supply Schedule and entered into contract with the VA, entered into contract with TRICARE
and successfully completed the Kaiser Permanente User Programme. While this has taken longer than we originally anticipated
, each one of these could result in a quantum leap in sales revenue as we bring them on board as commercial customers.”
The quantum leap turned out to be a leap back into the abyss - fictitious sales wrote off!
That just shows you how long it takes from getting a programme completed to getting it published, along with 2001 other contenders all trying to get their results published on 2001 other items.
And that is just page 1.
And published/peer reviewed it must be to be considered by others as qualifying for consideration.
Possibly the great numbers of researchers and programmes needing validation by publication that have proliferated over recent years would account for the delay as they are all trying to get in the door at once.
Bit like ex PEB shareholders when the time comes.
-
25-06-2019, 10:41 AM
#17022
Originally Posted by Minerbarejet
That just shows you how long it takes from getting a programme completed to getting it published, along with 2001 other contenders all trying to get their results published on 2001 other items.
And that is just page 1.
And published/peer reviewed it must be to be considered by others as qualifying for consideration.
Possibly the great numbers of researchers and programmes needing validation by publication that have proliferated over recent years would account for the delay as they are all trying to get in the door at once.
Bit like ex PEB shareholders when the time comes.
Delays indeed but actually, only for PEB with its bumbling management & directors.
Bunch of highly paid clowns running the company like a circus with an ever diminishing audience (shareholders) who are sick and fed up to the back teeth watching the same chimp juggling tricks of getting the audience to suck ever bigger lemons (capital raisings).
Last edited by Balance; 25-06-2019 at 10:50 AM.
-
25-06-2019, 10:44 AM
#17023
WOW
And I dont mean World of Warcraft.
-
25-06-2019, 10:48 AM
#17024
Originally Posted by Balance
Delays indeed but actually, only for PEB with its bumbling management & directors.
Bunch of highly paid clowns running the company like a circus with ever diminishing audience (shareholders) who are sick and fed up to the back teeth watching the same red-arsed monkey tricks of sucking lemons.
By golly, you're really back and on to PEB with gusto. Good on you Balance
-
25-06-2019, 10:50 AM
#17025
Member
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033563/
This link might help investors understand the differences between FDA and LDT. And vast benefits to LDT.
-
25-06-2019, 10:58 AM
#17026
Originally Posted by Carpenterjoe
Useful article which glaringly shows that PEB chose the wrong path, and has no basic understanding of how the medical industry works in the States :
Excerpt from article :
"While CMS is in the best position to address these gaps using the existing CLIA framework, it has shown a reluctance to do so and the FDA has stepped in. Nonetheless, it is hard to believe that the tools available to the FDA are a better fit for the task. While the FDA's goals are admirable in trying to bring regulatory coherence to the genetic testing industry, the FDA is imposing an undue regulatory burden that will change the industry in a way that harms providers and patients while not addressing the greatest problems."
Note that the article was published in 2015 !!!!! Plenty of notice to PEB that they must go the FDA way but what did the clowns do?
PEB sought to circumvent the FDA and has paid the price. Or rather, the audience (shareholder) has been sucking lemons and paying the price.
It's only been in recent months that we have seen only two directors put in some of their own money!!!!!!!
Last edited by Balance; 25-06-2019 at 11:04 AM.
-
25-06-2019, 11:46 AM
#17027
Originally Posted by Balance
Useful article which glaringly shows that PEB chose the wrong path, and has no basic understanding of how the medical industry works in the States :
Excerpt from article :
"While CMS is in the best position to address these gaps using the existing CLIA framework, it has shown a reluctance to do so and the FDA has stepped in. Nonetheless, it is hard to believe that the tools available to the FDA are a better fit for the task. While the FDA's goals are admirable in trying to bring regulatory coherence to the genetic testing industry, the FDA is imposing an undue regulatory burden that will change the industry in a way that harms providers and patients while not addressing the greatest problems."
Note that the article was published in 2015 !!!!! Plenty of notice to PEB that they must go the FDA way but what did the clowns do?
PEB sought to circumvent the FDA and has paid the price. Or rather, the audience (shareholder) has been sucking lemons and paying the price.
It's only been in recent months that we have seen only two directors put in some of their own money!!!!!!!
I would be hard pressed to call the CMS approval of a CLIA laboratory for the purposes of processing US based Triage outside of their home country as "showing reluctance."
The FDA would still be stuffing around with stage one because any slight alteration ie same test, different algorithm would require a complete restart.
-
25-06-2019, 12:46 PM
#17028
PEB took too long from the time their test was proven to getting to a broad market. In that time competing companies and new innovations have superceded their product. Doctors being doctors also, just cant help themselves by investing any surplus cash in further R and D. So PEB will never reap any rewards. Shareholders are really just using their funds for the good of mankind.
-
25-06-2019, 01:05 PM
#17029
Member
Originally Posted by bottomfeeder
PEB took too long from the time their test was proven to getting to a broad market. In that time competing companies and new innovations have superceded their product. Doctors being doctors also, just cant help themselves by investing any surplus cash in further R and D. So PEB will never reap any rewards. Shareholders are really just using their funds for the good of mankind.
bottomfeeder, please provide some evidence of another company that has 4 diagnostic tests specializing in BC. Or could you please enlighten me of these products that have superseded our product?
-
25-06-2019, 01:34 PM
#17030
Originally Posted by Carpenterjoe
bottomfeeder, please provide some evidence of another company that has 4 diagnostic tests specializing in BC. Or could you please enlighten me of these products that have superseded our product?
Interesting!
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks